|
- 2018
Germline genetic testing in prostate cancer – further enrichment in variant histologies?Abstract: The genetics and heritability of prostate cancer have been well studied and continue to be elucidated. Recently, germline mutations in homologous recombination (HR) DNA repair genes have been observed in a significant proportion of men with prostate cancer. Based on the pioneering work in breast and ovarian cancers, pharmacological targeting of the poly-ADP ribose polymerase (PARP) enzyme has been shown to induce synthetic lethality in HR-deficient tumors. The discovery and characterization of germline HR mutations in prostate cancer patients may increase therapeutic options and lead to improved clinical outcomes
|